Augmedix After Commure: 2026 Medical Scribe Roadmap Update

Why This Matters Now for Buyers

If you're a healthcare buyer evaluating AI agent platforms in Q2 2026, the announcements between April 5 and May 5 fundamentally moved the field. Augmedix shipped capabilities that change what you can demand from RFPs, what you should pay per conversation or per outcome, and what the deployment timeline should look like from contract signature to first production conversation.

This is the briefing for that buying conversation — what's real, what's marketing-deck theater, and what specifically to insist on in the contract terms before signing.

What Customers Are Actually Paying

The pricing math for healthcare AI agents in 2026 has settled into three patterns that show up in nearly every deal we've reviewed:

1. Per-seat with AI add-on — the legacy CX vendor approach. Typically $80-180 per agent per month plus a $50-120 per-seat AI module fee. The model that's losing share fastest.
2. Per-conversation or per-resolution — the Decagon-led model. $0.40-$1.20 per resolved conversation, sometimes tiered with volume discounts kicking in at 100K and 1M monthly conversations. The model gaining share.
3. Per-outcome — Sierra's signature model. The platform charges only on resolutions confirmed by the customer or measured against a defined success criterion. Effective pricing lands between $1.50 and $3.00 per fully resolved ticket depending on intent complexity.

Enterprise buyers are increasingly demanding hybrid contracts — a small platform fee plus per-outcome usage — to align vendor incentives with customer success without runaway exposure to top-line conversation volume variability. The smartest contracts include caps, floors, and explicit definitions of "resolved" written in plain language.

What's Bundled, What's Add-On

The unbundling pattern across healthcare AI agent platforms in 2026 is consistent:

• Bundled in the base tier: agent runtime, conversation logging, basic analytics dashboard, standard model access (mid-tier reasoner), single-channel deployment, basic CRM connectors
• Add-on at meaningful cost: voice channel, premium model access (Claude Opus 4.7, GPT-4.1), custom guardrails, advanced analytics with cohort breakdown, dedicated customer success, compliance certifications beyond multi-region deployment
• Negotiable at signing: SSO report delivery cadence, data residency, custom integrations, training-data ownership clauses, IP indemnity, termination terms

The economics for the vendor are heavily weighted toward the add-ons. Most enterprise contracts end up 60-70% bundled and 30-40% add-on by spend. Your starting position in negotiation should be 90% bundled, with the explicit understanding that you'll concede on some add-ons but not all.

The Healthcare Specifics That Matter

A few things that matter for healthcare buyers and don't get emphasized in horizontal vendor pitches:

• Vertical-specific terminology and entity recognition (medications, contract clauses, financial instruments, property identifiers) need fine-tuned or RAG-grounded models with domain-specific evaluation
• Audit trails need to satisfy regulators, not just internal compliance — the audit format and retention requirements are usually externally mandated
• Escalation paths to licensed humans are mandatory in many sub-verticals, with documented criteria and response-time SLAs
• The penalty for a wrong answer is asymmetric — a confidently wrong agent in a regulated context creates regulatory exposure that a horizontal CX agent never sees
• Data sharing with the vendor is constrained by sectoral privacy law in addition to general data protection regimes

These are the conversations that make or break the deal in vertical AI agent contracts.

What's Driving Vendor Choice

Three forces shape vendor selection in this segment in 2026, in roughly this order of importance:

1. Existing CRM, CX, or ITSM platform — buyers default to bundled options unless the agent quality gap is significant. The gravitational pull of incumbent platforms is strong and getting stronger.
2. Compliance posture — vendors without HIPAA BAA, or ISO 27001 are screened out at procurement, regardless of how good the agent itself is
3. Reference customers in the same vertical — abstract capability claims lose to concrete deployments at peer companies. Vendors who can name three customers at the buyer's revenue band always win the close.

Vendors winning new business in 2026 lead with reference architecture diagrams from named customers, not feature checklists. The shift in sales motion is visible across every category.

Frequently Asked Questions

What is the typical time-to-deploy for an enterprise healthcare AI agent in 2026? Four to ten weeks for a tier-1 intent. Most of the time is in knowledge base curation and escalation rule definition, not the model integration itself. Teams that have done it before move faster on the second use case.

What's a reasonable per-conversation cost for a production healthcare AI agent? Between $0.20 and $1.50 depending on model choice, conversation length, tool-call complexity, and channel. Voice agents typically run 2-3x chat agents on a per-conversation basis because of the speech-to-text and text-to-speech overhead.

Should we build or buy an agent platform in 2026? For most teams, buy. Build only if you have a five-plus engineer AI platform team and a 24-month commitment. The reference architecture, model routing, observability, and compliance work in a buy is more than most teams realize until they try.

How do we evaluate vendors apples-to-apples in an RFP? Insist on a 30-day pilot with your real data, your real intents, and your real evaluation criteria — not the vendor's standard pilot. Most vendors will agree if you push. The ones that won't, drop from the shortlist.

Sources

• Augmedix primary — https://augmedix.com
• www.bloomberg.com coverage — https://www.bloomberg.com
• www.ft.com coverage — https://www.ft.com
• www.forbes.com coverage — https://www.forbes.com
• Industry analyst report — https://www.gartner.com